Amphastar Pharmaceuticals (AMPH) Jefferies Global Healthcare Conference 2026 summary

Company Overview and Strategic Direction

• Focus on complex generics, hospital injectables, and expansion into proprietary and biosimilar products, with several proprietary and three biosimilar products in development.

• Technical expertise in peptides and clinical trials supports movement into higher-value proprietary products.

• Operates a fully integrated, one-stop business model with in-house R&D, manufacturing, and distribution, ensuring quality and compliance.

• Strategic R&D investment of $369M over five years supports a diverse and scalable proprietary pipeline.

• Willingness to invest up to $500 million in new product acquisitions, with a focus on portfolio balance.

Pipeline and Product Development

• Proprietary and biosimilar products are projected to comprise 85% of the pipeline by 2026, up from 37% in 2021.

• Proprietary pipeline includes first-in-class peptides for oncology, ophthalmology, and rheumatology, with several candidates advancing through preclinical and clinical stages.

• Three interchangeable biosimilars are in development, including insulin aspart and recombinant human insulin, with commercial launches expected in 2027.

• First biosimilar (insulin aspart) under FDA review, targeting 2027 launch and interchangeability status.

• Synthetic corticotropin asset in preclinical stage, aiming for IND filing in 2027; U.S. data likely required despite Chinese studies.

Revenue Drivers and Product Performance

• Mid to high single-digit revenue growth expected, driven primarily by the generic Atrovent (ipratropium bromide) launch with six months exclusivity.

• Generic Atrovent could generate around $40 million annually as sole provider, assuming no authorized generic launches.

• BAQSIMI® acquisition expands proprietary Rx portfolio, with peak annual sales projected at $250–$275M and incremental adjusted EPS of $2.00–$2.50.

• Primatene MIST® remains the only FDA-approved OTC asthma inhaler, with high single-digit growth forecasted for 2026 and a new green propellant version in development.

• Existing products provide a diversified revenue base, with new launches further strengthening market position.